BRPI0908849A2 - Composto e composições como c-kit e inibidores de pdgfr quinase - Google Patents

Composto e composições como c-kit e inibidores de pdgfr quinase

Info

Publication number: BRPI0908849A2
Authority: BR; Brazil
Prior art keywords: kit; compositions; compound; kinase inhibitors; pdgfr kinase
Prior art date: 2008-02-22

Application number

BRPI0908849-0A

Other languages

English (en)

Inventor

Xiaolin Li

Xiaodong Liu

Jon Loren

Valentina Molteni

Juliet Nabakka

Vince Yee

Donatella Chianelli

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-22

Filing date

2009-02-20

Publication date

2015-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40577860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908849(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-20 Application filed by Irm Llc filed Critical Irm Llc

2015-08-25 Publication of BRPI0908849A2 publication Critical patent/BRPI0908849A2/pt

Links

101150093908 PDGFRB gene Proteins 0.000 title 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title 1
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Addiction (AREA)
Psychology (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)

BRPI0908849-0A 2008-02-22 2009-02-20 Composto e composições como c-kit e inibidores de pdgfr quinase BRPI0908849A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3091208P	2008-02-22	2008-02-22
PCT/US2009/034778 WO2009105712A1 (en)	2008-02-22	2009-02-20	Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0908849A2 true BRPI0908849A2 (pt)	2015-08-25

Family

ID=40577860

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0908849-0A BRPI0908849A2 (pt)	2008-02-22	2009-02-20	Composto e composições como c-kit e inibidores de pdgfr quinase

Country Status (17)

Country	Link
US (1)	US8278452B2 (pt)
EP (1)	EP2252612B1 (pt)
JP (1)	JP5230755B2 (pt)
KR (1)	KR101216323B1 (pt)
CN (1)	CN102083828B (pt)
AR (1)	AR070469A1 (pt)
AT (1)	ATE551342T1 (pt)
AU (1)	AU2009217356B2 (pt)
BR (1)	BRPI0908849A2 (pt)
CA (1)	CA2714700C (pt)
CL (1)	CL2009000400A1 (pt)
EA (1)	EA018551B1 (pt)
ES (1)	ES2383331T3 (pt)
MX (1)	MX2010009207A (pt)
PE (1)	PE20091492A1 (pt)
TW (1)	TW200940538A (pt)
WO (1)	WO2009105712A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011049625A1 (en)	2009-10-20	2011-04-28	Mansour Samadpour	Method for aflatoxin screening of products
SG10201500895XA (en)	2009-11-05	2015-04-29	Rhizen Pharmaceuticals Sa	Chromen-4-one Derivatives As Kinase Modulators
TWI619713B (zh)	2010-04-21	2018-04-01	普雷辛肯公司	用於激酶調節的化合物和方法及其適應症
EP2680846A4 (en) *	2011-03-01	2014-08-06	Npharmakon Llc	USE OF N- (4-METHOXYPHENYL) -1-PHENYL-1H-PYRAZOL-3-AMINE AND COMPOUNDS ASSOCIATED THEREWITH
RS58326B1 (sr)	2011-05-04	2019-03-29	Rhizen Pharmaceuticals S A	Nova jedinjenja kao modulatori proteinskih kinaza
HK1200459A1 (en) *	2011-09-19	2015-08-07	Gencia Corporation	Modified creatine compounds
SG10201610936RA (en)	2011-12-22	2017-02-27	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
HUE029038T2 (en)	2012-05-25	2017-01-30	Janssen Sciences Ireland Uc	Uracil spirooxetan nucleosides
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
DK3366293T3 (da) *	2012-06-07	2020-06-15	Deciphera Pharmaceuticals Llc	Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme
CN109970742A (zh)	2012-07-04	2019-07-05	理森制药股份公司	选择性PI3Kδ抑制剂
GEP201706757B (en)	2012-12-21	2017-10-25	Alios Biopharma Inc	Substituted nucleosides, nucleotides and analogs thereof
CN105814028B (zh)	2013-09-06	2018-02-16	奥瑞基尼探索技术有限公司	作为免疫调节剂的1，2，4‑*二唑衍生物
CN104458675A (zh) *	2013-09-12	2015-03-25	中国药科大学	一种筛选干细胞因子受体激酶抑制剂高通量筛选方法
CN104458674A (zh) *	2013-09-12	2015-03-25	中国药科大学	一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
JP6562908B2 (ja)	2013-10-11	2019-08-21	ヤンセンバイオファーマインク．	置換ヌクレオシド、置換ヌクレオチドおよびその類似体
JP2018507894A (ja) *	2015-03-10	2018-03-22	オーリジーンディスカバリーテクノロジーズリミテッドＡｕｒｉｇｅｎｅＤｉｓｃｏｖｅｒｙＴｅｃｈｎｏｌｏｇｉｅｓＬｉｍｉｔｅｄ	免疫調節剤としての３−置換−１，２，４−オキサジアゾールおよびチアジアゾール化合物
KR102894264B1 (ko)	2015-03-10	2025-12-02	오리진 온콜로지 리미티드	면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
RS62626B1 (sr) *	2016-01-11	2021-12-31	Merck Patent Gmbh	Derivati hinolin-2-ona
WO2019061324A1 (en)	2017-09-29	2019-04-04	Curis Inc.	CRYSTALLINE FORMS OF IMMUNOMODULATORS
US11136300B2 (en)	2017-10-11	2021-10-05	Aurigene Discovery Technologies Limited	Crystalline forms of 3-substituted 1,2,4-oxadiazole
SG11202003625VA (en)	2017-11-03	2020-05-28	Aurigene Discovery Tech Ltd	Dual inhibitors of tim-3 and pd-1 pathways
EP3706798A1 (en)	2017-11-06	2020-09-16	Aurigene Discovery Technologies Limited	Conjoint therapies for immunomodulation
AU2019216351B2 (en)	2018-01-31	2024-07-25	Deciphera Pharmaceuticals, Llc	Combination therapy for the treatment of mastocytosis
EP3746059B1 (en)	2018-01-31	2026-03-04	Deciphera Pharmaceuticals, LLC	Combination therapy for the treatment of gastrointestinal stromal tumors
US11472781B2 (en)	2018-02-21	2022-10-18	Southern Research Institute	2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
US11718593B2 (en)	2018-05-17	2023-08-08	Southern Research Institute	2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases
WO2020185812A1 (en)	2019-03-11	2020-09-17	Teva Pharmaceuticals International Gmbh	Solid state forms of ripretinib
EP3942045A1 (en)	2019-03-21	2022-01-26	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AR118826A1 (es)	2019-05-03	2021-11-03	Kinnate Biopharma Inc	Inhibidores de cinasas raf
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
FI4013412T3 (fi)	2019-08-12	2026-03-24	Deciphera Pharmaceuticals Llc	Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
BR112022007612A2 (pt)	2019-10-24	2022-09-20	Kinnate Biopharma Inc	Inibidores de raf quinases
EP4054579A1 (en)	2019-11-08	2022-09-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
PL4084779T3 (pl)	2019-12-30	2025-02-24	Deciphera Pharmaceuticals, Llc	Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en)	2019-12-30	2023-08-31	Deciphera Pharmaceuticals, Llc	Amorphous kinase inhibitor formulations and methods of use thereof
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
US11407737B2 (en)	2020-09-18	2022-08-09	Kinnate Biopharma Inc.	Inhibitors of RAF kinases
WO2022081469A1 (en)	2020-10-12	2022-04-21	Kinnate Biopharma Inc.	Inhibitors of raf kinases
EP4326256A4 (en)	2021-04-23	2025-03-19	Pierre Fabre Medicament	Treating cancer with a RAF inhibition
CN113662938B (zh) *	2021-09-26	2022-08-16	广西科技大学	一种胺类衍生物在制备抗肿瘤药物组合物中的应用
CN118974036A (zh)	2022-02-03	2024-11-15	皮埃尔法布雷医药公司	Raf激酶的抑制剂
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
CN117263852A (zh) *	2023-08-24	2023-12-22	贵州大学	取代3-(吡啶-2-基)苯氨基衍生物、其制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW486479B (en) *	1997-07-15	2002-05-11	Dainippon Pharmaceutical Co	5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1H)-one derivatives
AU742999B2 (en)	1997-08-20	2002-01-17	Warner-Lambert Company	Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6822097B1 (en)	2002-02-07	2004-11-23	Amgen, Inc.	Compounds and methods of uses
US7196090B2 (en) *	2002-07-25	2007-03-27	Warner-Lambert Company	Kinase inhibitors
JP4758349B2 (ja) *	2003-10-08	2011-08-24	アイアールエム・リミテッド・ライアビリティ・カンパニー	タンパク質キナーゼ阻害剤としての化合物および組成物
US20070054916A1 (en) *	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
GT200500321A (es) *	2004-11-09	2006-09-04		Compuestos y composiciones como inhibidores de proteina kinase.
WO2006071940A2 (en) *	2004-12-23	2006-07-06	Deciphera Pharmaceuticals, Llc	Enzyme modulators and treatments
JP2008525502A (ja) *	2004-12-23	2008-07-17	デシファラファーマスーティカルズ，エルエルシー	抗炎症薬
AU2006279992A1 (en) *	2005-08-09	2007-02-22	Irm Llc	Compounds and compositions as protein kinase inhibitors
JP5335426B2 (ja)	2005-09-27	2013-11-06	アイアールエム・リミテッド・ライアビリティ・カンパニー	ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
MX2008014618A (es)	2006-05-15	2008-11-28	Irm Llc	Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US7897762B2 (en) *	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en)	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN101528744A (zh)	2006-10-20	2009-09-09	Irm责任有限公司	用于调节c-kit和pdgfr受体的组合物和方法
EP2152688A1 (en)	2007-05-04	2010-02-17	Irm Llc	Compounds and compositions as c-kit and pdgfr kinase inhibitors
WO2008137605A1 (en)	2007-05-04	2008-11-13	Irm Llc	Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors

2009
- 2009-02-20 AT AT09711557T patent/ATE551342T1/de active
- 2009-02-20 US US12/918,801 patent/US8278452B2/en not_active Expired - Fee Related
- 2009-02-20 CN CN2009801139589A patent/CN102083828B/zh not_active Expired - Fee Related
- 2009-02-20 PE PE2009000257A patent/PE20091492A1/es not_active Application Discontinuation
- 2009-02-20 CA CA2714700A patent/CA2714700C/en not_active Expired - Fee Related
- 2009-02-20 MX MX2010009207A patent/MX2010009207A/es active IP Right Grant
- 2009-02-20 BR BRPI0908849-0A patent/BRPI0908849A2/pt not_active IP Right Cessation
- 2009-02-20 CL CL2009000400A patent/CL2009000400A1/es unknown
- 2009-02-20 AU AU2009217356A patent/AU2009217356B2/en not_active Ceased
- 2009-02-20 EP EP09711557A patent/EP2252612B1/en not_active Not-in-force
- 2009-02-20 WO PCT/US2009/034778 patent/WO2009105712A1/en not_active Ceased
- 2009-02-20 EA EA201001331A patent/EA018551B1/ru not_active IP Right Cessation
- 2009-02-20 KR KR1020107021103A patent/KR101216323B1/ko not_active Expired - Fee Related
- 2009-02-20 ES ES09711557T patent/ES2383331T3/es active Active
- 2009-02-20 JP JP2010547818A patent/JP5230755B2/ja not_active Expired - Fee Related
- 2009-02-23 TW TW098105719A patent/TW200940538A/zh unknown
- 2009-02-24 AR ARP090100626A patent/AR070469A1/es unknown

Also Published As

Publication number	Publication date
KR20100115379A (ko)	2010-10-27
CN102083828B (zh)	2013-11-13
JP5230755B2 (ja)	2013-07-10
EP2252612A1 (en)	2010-11-24
US20110183997A1 (en)	2011-07-28
MX2010009207A (es)	2011-03-03
CL2009000400A1 (es)	2010-09-10
ES2383331T3 (es)	2012-06-20
WO2009105712A1 (en)	2009-08-27
PE20091492A1 (es)	2009-10-22
AU2009217356B2 (en)	2012-05-03
CA2714700C (en)	2013-07-30
EA201001331A1 (ru)	2011-04-29
US8278452B2 (en)	2012-10-02
AR070469A1 (es)	2010-04-07
ATE551342T1 (de)	2012-04-15
AU2009217356A1 (en)	2009-08-27
JP2011513231A (ja)	2011-04-28
TW200940538A (en)	2009-10-01
CA2714700A1 (en)	2009-08-27
KR101216323B1 (ko)	2012-12-27
EP2252612B1 (en)	2012-03-28
CN102083828A (zh)	2011-06-01
EA018551B1 (ru)	2013-08-30

Legal Events

Date	Code	Title	Description
2016-04-19	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-08-30	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0811516A2 (pt)	2014-11-18	Compostos e composições como inibidores de c-kit e pdgfr cinase
CY2019027I2 (el)	2019-11-27	Παραγωγα φωσφορου ως αναστολεις κινασης
BRPI0912668A2 (pt)	2016-01-26	composto e composições como inibidores de quinase
CY2020024I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
BRPI0914652A2 (pt)	2017-06-06	compostos e composições como inibidores de quinase
LTPA2019006I1 (lt)	2019-03-25	Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai
BRPI0911228A2 (pt)	2017-05-30	compostos e composições como inibidores de proteínas quinase
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0906973A2 (pt)	2015-07-14	Compostos e composições como inibidores de cinase.
BRPI0811517A2 (pt)	2014-11-18	Compostos e composições como inibidores de c-kit e pdgfr cinase.
CO6900141A2 (es)	2014-03-20	Compuestos y composiciones como inhibidores de la quinasa c-kit
CO6900140A2 (es)	2014-03-20	Compuestos y composiciones como inhibidores de la quinasa c-kit
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
BRPI0910979A2 (pt)	2016-01-05	compostos e composições como inibidores de quinase
BRPI0914545A2 (pt)	2017-05-23	compostos e composições como inibidores de quinase
BRPI0912475A2 (pt)	2018-01-09	compostos como inibidores de quinase
SMT201400154B (it)	2015-01-15	Composti di triazolopiridina come inibitori di chinasi pim
ATE551342T1 (de)	2012-04-15	Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
ES2598358T8 (es)	2017-02-13	Derivados de quinolina como inhibidores de PI3K quinasa
BRPI0811065A2 (pt)	2014-12-02	Indazóis 5-heteroaril substituídos como inibidores de quinase
BR112012004448A2 (pt)	2017-05-30	"compostos e composições como inibidores de proteína cinase"
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI0812825A2 (pt)	2014-12-09	Derivados ftalazinona como inibidores de parp-1
BRPI0920239A2 (pt)	2019-09-24	compostos heterocíclicos como inibidores de proteínas quinases